218 related articles for article (PubMed ID: 34195677)
1. CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice.
Li N; Torres MB; Spetz MR; Wang R; Peng L; Tian M; Dower CM; Nguyen R; Sun M; Tai CH; de Val N; Cachau R; Wu X; Hewitt SM; Kaplan RN; Khan J; St Croix B; Thiele CJ; Ho M
Cell Rep Med; 2021 Jun; 2(6):100297. PubMed ID: 34195677
[TBL] [Abstract][Full Text] [Related]
2. GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.
Heitzeneder S; Bosse KR; Zhu Z; Zhelev D; Majzner RG; Radosevich MT; Dhingra S; Sotillo E; Buongervino S; Pascual-Pasto G; Garrigan E; Xu P; Huang J; Salzer B; Delaidelli A; Raman S; Cui H; Martinez B; Bornheimer SJ; Sahaf B; Alag A; Fetahu IS; Hasselblatt M; Parker KR; Anbunathan H; Hwang J; Huang M; Sakamoto K; Lacayo NJ; Klysz DD; Theruvath J; Vilches-Moure JG; Satpathy AT; Chang HY; Lehner M; Taschner-Mandl S; Julien JP; Sorensen PH; Dimitrov DS; Maris JM; Mackall CL
Cancer Cell; 2022 Jan; 40(1):53-69.e9. PubMed ID: 34971569
[TBL] [Abstract][Full Text] [Related]
3. Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma.
Li N; Fu H; Hewitt SM; Dimitrov DS; Ho M
Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6623-E6631. PubMed ID: 28739923
[TBL] [Abstract][Full Text] [Related]
4. An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma.
Tian M; Cheuk AT; Wei JS; Abdelmaksoud A; Chou HC; Milewski D; Kelly MC; Song YK; Dower CM; Li N; Qin H; Kim YY; Wu JT; Wen X; Benzaoui M; Masih KE; Wu X; Zhang Z; Badr S; Taylor N; Croix BS; Ho M; Khan J
J Clin Invest; 2022 Aug; 132(16):. PubMed ID: 35852863
[TBL] [Abstract][Full Text] [Related]
5. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma.
Sun L; Gao F; Gao Z; Ao L; Li N; Ma S; Jia M; Li N; Lu P; Sun B; Ho M; Jia S; Ding T; Gao W
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833049
[TBL] [Abstract][Full Text] [Related]
6. Development of Glypican-2 Targeting Single-Domain Antibody CAR T Cells for Neuroblastoma.
Li N; Ho M
Methods Mol Biol; 2022; 2446():451-468. PubMed ID: 35157288
[TBL] [Abstract][Full Text] [Related]
7. Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors.
Foster JB; Griffin C; Rokita JL; Stern A; Brimley C; Rathi K; Lane MV; Buongervino SN; Smith T; Madsen PJ; Martinez D; Delaidelli A; Sorensen PH; Wechsler-Reya RJ; Karikó K; Storm PB; Barrett DM; Resnick AC; Maris JM; Bosse KR
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36167467
[TBL] [Abstract][Full Text] [Related]
8. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.
Li D; Li N; Zhang YF; Fu H; Feng M; Schneider D; Su L; Wu X; Zhou J; Mackay S; Kramer J; Duan Z; Yang H; Kolluri A; Hummer AM; Torres MB; Zhu H; Hall MD; Luo X; Chen J; Wang Q; Abate-Daga D; Dropulic B; Hewitt SM; Orentas RJ; Greten TF; Ho M
Gastroenterology; 2020 Jun; 158(8):2250-2265.e20. PubMed ID: 32060001
[TBL] [Abstract][Full Text] [Related]
9. Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma.
Sun M; Cao Y; Okada R; Reyes-González JM; Stack HG; Qin H; Li N; Seibert C; Kelly MC; Ruppin E; Ho M; Thiele CJ; Nguyen R
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36631162
[TBL] [Abstract][Full Text] [Related]
10. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
[TBL] [Abstract][Full Text] [Related]
11. GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab.
Kato D; Yaguchi T; Iwata T; Katoh Y; Morii K; Tsubota K; Takise Y; Tamiya M; Kamada H; Akiba H; Tsumoto K; Serada S; Naka T; Nishimura R; Nakagawa T; Kawakami Y
Elife; 2020 Mar; 9():. PubMed ID: 32228854
[TBL] [Abstract][Full Text] [Related]
12. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
13. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G
Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824
[TBL] [Abstract][Full Text] [Related]
14. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
Chen C; Li K; Jiang H; Song F; Gao H; Pan X; Shi B; Bi Y; Wang H; Wang H; Li Z
Cancer Immunol Immunother; 2017 Apr; 66(4):475-489. PubMed ID: 28035433
[TBL] [Abstract][Full Text] [Related]
15. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
[TBL] [Abstract][Full Text] [Related]
16. Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma.
Meng M; Wu YC
J Immunol Res; 2021; 2021():1782728. PubMed ID: 34527749
[TBL] [Abstract][Full Text] [Related]
17. CAR T Cell Therapy for Neuroblastoma.
Richards RM; Sotillo E; Majzner RG
Front Immunol; 2018; 9():2380. PubMed ID: 30459759
[TBL] [Abstract][Full Text] [Related]
18. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
[TBL] [Abstract][Full Text] [Related]
19. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma.
Moghimi B; Muthugounder S; Jambon S; Tibbetts R; Hung L; Bassiri H; Hogarty MD; Barrett DM; Shimada H; Asgharzadeh S
Nat Commun; 2021 Jan; 12(1):511. PubMed ID: 33479234
[TBL] [Abstract][Full Text] [Related]
20. Use of a Single CAR T Cell and Several Bispecific Adapters Facilitates Eradication of Multiple Antigenically Different Solid Tumors.
Lee YG; Marks I; Srinivasarao M; Kanduluru AK; Mahalingam SM; Liu X; Chu H; Low PS
Cancer Res; 2019 Jan; 79(2):387-396. PubMed ID: 30482775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
